SILVER SPRING, Md., Nov. 28, 2011 /PRNewswire-USNewswire/ -- Science, public health, and regulatory highlights from the U.S. Food and Drug Administration. Information in this document is designed for credentialed journalists. Release dates and times for items are current as of November 28, 2011.
(Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO)
FDA News & Notes does not contain any regulatory or enforcement actions due to legal limitations.
Events and Speeches for the Commissioner and FDA leadership:
Tuesday, 11/29 – ECRI Institute's 18th Annual Conference titled "Patient-Centeredness in Policy and Practice: A conference on evidence, programs, and implications." FDA Commissioner Hamburg, M.D., joins Carolyn Clancy, M.D., director of the Agency for Healthcare Research and Quality, Jeffrey Shuren, M.D., director of the FDA's Center for Devices and Radiologic Health, Janet Woodcock, M.D., director of the FDA's Center for Drug Evaluation and Research, and others at the conference. 8:30 a.m., 10903 New Hampshire Avenue, Building 31, Room 1503, Silver Spring, Md.
Press Office Contact: Karen Riley, 301-796-4674, [email protected]
Wednesday, 11/30 – FDA Commissioner Margaret A. Hamburg, M.D., speaks at the Critical Path Institute meeting titled Creating Consensus Science. 8:15 a.m., Crowne Plaza Hotel, 8777 Georgia Ave., Silver Spring, Md.
Press Office Contact: Raymond Formanek, Jr., 301-796-4677, [email protected]
Meetings, Workshops and Congressional Testimony:
Wednesday, 11/30 – The Public Meeting on Cosmetic Microbiological Safety Issues provides stakeholders with an opportunity to present information regarding cosmetic microbiological safety and to suggest areas for possible FDA guidance documents. 9 a.m., L'Enfant Plaza Hotel, 480 L'Enfant Plaza S.W., Washington, D.C.
Press Office Contact: Tamara Ward, 301-796-7567, [email protected]
Thursday, 12/1 – Drug Safety and Risk Management Advisory Committee and the Dermatologic and Ophthalmic Drugs Advisory Committee meet in joint session to discuss REMS-related topics. In the morning, the committees will discuss the REMS program for isotretinoin, also known as iPLEDGE, as an example of a REMS that has Elements to Assure Safe Use (ETASU). During the afternoon session, the committees discuss issues related to the impact of REMS with ETASU on the health care system and patient access. A live webcast will be available. 8 a.m., 10903 New Hampshire Avenue, Building 31, Room 1503, Silver Spring, Md.
Press Office Contact: Morgan Liscinsky, 301-796-0397, [email protected]
FDA Office of Public Affairs Contact Information:
Call or email FDA Office of Public Affairs, 301-796-4540, [email protected]
List of FDA press officers and beats
More Resources:
FDA News and Events
FDA Photos (Flickr)
Consumer Health Information
SOURCE U.S. Food and Drug Administration
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article